Business Context and Reporting Period
This Form 6-K filing covers the month of January 2011 for Prana Biotechnology Limited (ASX: PBT), a foreign private issuer based in Australia. The filing serves as a Final Director's Interest Notice pursuant to ASX Listing Rule 3.19A.3 and Section 205G of the Corporations Act.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings and does not contain financial performance data.
Material Changes
The primary material change reported is the cessation of Paul Marks as a Director of the company effective January 4, 2011. The filing details his relevant interests in securities at the time of departure.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a compliance notice regarding director interests.
Important Facts for Investors
- Director Departure: Paul Marks ceased to be a Director on January 4, 2011.
- Direct Shareholdings: At the time of departure, Paul Marks was the registered holder of 8,589,361 shares.
- Indirect Shareholdings: Paul Marks held relevant interests in 7,829,263 shares via JJ Holdings (VIC) Pty Ltd and 760,098 shares via Summerlea S/Fund A/C.
- Total Interest: The combined disclosed interest totals 17,178,722 shares.
- Options: No options were held by the director at the time of the notice.